Mar. 29, 2010
US drug manufacturer Eli Lilly plans to launch 15 new products in China within the next five years. Eli Lilly is planning to grow significantly in the next few years after achieving sales of $270 million in China last year.
Eli Lilly's $100 million venture capital fund focused on life sciences and healthcare in China is one of the most active venture capital investors in China's biopharmaceutical industry.
According to its CEO, John Lechleiter, Eli Lilly had established positions in the fastest growing therapeutic areas in China, including oncology and diabetes, and is investing in the education of Chinese doctors so that they would be ready to pursue future roles in clinical trials.